Active Implantable Medical Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

Active Implantable Medical Devices Market by Product Type (Implantable Cardiovascular Devices [Implantable Cardioverter Defibrillators, Ventricular Assist Devices, Implantable Pacemakers, and Implantable Cardiac Monitors/Insertable Loop Recorders], Implantable Neurostimulators [Deep Brain Stimulators, Spinal Cord Stimulators, Sacral Nerve Stimulators, and Others] Hearing Implants, and Others), End-User (Hospitals, Ambulatory Surgical Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing instances of chronic disorders and the rising product developmental activities across the world

The active implantable medical devices market was valued at USD 25 billion in 2023, growing at a CAGR of 7.55% during the forecast period from 2024 to 2030 to reach USD 38.57 billion by 2030. The active implantable medical devices market is observing substantial market growth primarily owing to the increasing instances of chronic disorders like neurological disorders including multiple sclerosis, epilepsy, chronic lower back pain, increasing regulatory approvals, and the rising preference for minimally invasive procedures that are anticipated to further accelerate the overall growth of the active implantable medical devices market during the forecast period from 2024 to 2030.

Active Implantable Medical Devices Market Dynamics:

As per data from the World Health Organization (WHO) (2023), it was reported that over 1.8 million people worldwide are affected by multiple sclerosis (MS). It impacts various functions including cognitive, emotional, motor, sensory, and visual abilities. It occurs when the immune system mistakenly attacks the brain and spinal cord. Data from the WHO stated that in 2024, around 50 million people worldwide had epilepsy, making it one of the most common neurological diseases globally.

In MS, neurostimulators are used to alleviate symptoms such as spasticity and chronic pain by modulating neural activity in the spinal cord or peripheral nerves. For epilepsy, implantable neurostimulators and responsive neurostimulation devices help reduce the frequency and severity of seizures by delivering targeted electrical impulses to the brain.

As per the data from WHO (2023), in 2020, there were 619 million cases of lower back pain and it is projected that the number of lower back pain cases will rise to 843 million by 2050.

Data from the European Pain Federation (2023), stated that 740 million people globally experience an episode of severe pain at some point in their lives on average. For approximately 20% of these individuals, the pain persists for longer than three months, thereby categorizing it as chronic pain. Active implantable medical devices like spinal cord and peripheral nerve stimulators manage chronic and severe pain by delivering targeted electrical stimulation to disrupt pain signals, offering personalized, non-opioid pain relief and improving quality of life.

Additionally, in December 2022, Abbott Laboratories announced the U.S. Food and Drug Administration (FDA) approval for the Eterna spinal cord stimulation system, which was recognized as the smallest implantable, rechargeable spinal cord stimulator that is available for the treatment of chronic pain.

Therefore, all the factors stated above collectively will drive the overall active implantable medical devices market growth.

However, the availability of alternative devices & therapy, malfunction due to hardware failure, software errors, or battery depletion, among others may prove to be challenging factors for the active implantable medical devices market growth.

Active Implantable Medical Devices Market Segment Analysis:

Active Implantable Medical Devices Market by Product Type (Implantable Cardiovascular Devices [Implantable Cardioverter Defibrillators, Ventricular Assist Devices, Implantable Pacemakers, and Implantable Cardiac Monitors/Insertable Loop Recorders], Implantable Neurostimulators [Deep Brain Stimulators, Spinal Cord Stimulators, Sacral Nerve Stimulators, and Others] Hearing Implants, and Others), End-User (Hospitals, Ambulatory Surgical Centres, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the active implantable medical devices market, the implantable neurostimulators category is expected to have a significant revenue share in the year 2023. This can be ascribed to various key features and advantages offered by these devices.

Key features of these devices include precise, programmable stimulation settings that allow for personalized therapy adjustments, rechargeable, and minimally invasive implantation procedures. Advantages include targeted symptom relief, reduced dependency on medications, improved quality of life, and the ability to make real-time adjustments through external controllers. Additionally, many modern neurostimulators offer remote monitoring and adaptive stimulation, which automatically adjusts to the patient's activity level, enhancing treatment efficacy and patient comfort.

Moreover, new product approvals are likely to upsurge the market for the same. For example, in August 2023, Medtronic announced that it received CE Mark approval for the Inceptiv closed-loop rechargeable spinal cord stimulator implant.

Therefore the various features and advantages of implantable neurostimulators solidify the significant impact on the growth of the overall active implantable medical devices market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall active implantable medical devices market:

Among all the regions, North America is expected to dominate the active implantable medical devices market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030. This can be attributed to several factors, including the increasing prevalence of hearing loss, the growing burden of cardiovascular disorders in the region including myocardial infarction, and ongoing product developmental activities by regulatory bodies that are acting as key factors contributing to the growth of the active implantable medical devices market in the North America region.

As per data from WHO (2024), in 2021, 217 million people were living with hearing loss in the US. The same source further stated that by 2050, 322 million people would be affected by hearing problems in the US. Active implantable medical devices, such as cochlear implants, play a crucial role in managing hearing loss by directly stimulating the auditory nerve and bypassing damaged parts of the ear to restore hearing function.

According to data from the Centers for Disease Control and Prevention (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Also, data from the Canadian Institute for Health Information (2024), stated that in 2022, 2.4 million Canadians were affected by heart disease. Active implantable medical devices are critical in managing heart disease and myocardial infarction by providing real-time monitoring, regulating heart rhythm, and preventing life-threatening cardiac events. In individuals with heart attacks, devices like implantable cardioverter defibrillators and pacemakers help detect abnormal heart rhythms and restore normal function, reducing the risk of sudden cardiac arrest.

Product developmental activities initiated by regulatory bodies will further boost the market for active implantable medical devices. For example, in June 2024, Elutia Inc., a pioneer in drug-eluting biomatrix products, announced that Antibiotic-Eluting BioEnvelope, EluPro (previously known as CanGaroo during development), received clearance from the U.S. Food and Drug Administration (FDA). Designed to prevent post-operative complications for devices like implantable pacemakers and defibrillators, EluPro integrated potent antibiotic therapy with advanced tissue engineering.

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American active implantable medical devices market.

Active Implantable Medical Devices Market key players:

Some of the key market players operating in the active implantable medical devices market include Medtronic, Abbott, Jarvik Heart, Inc., Biotronik SE & Co. KG, Boston Scientific Corporation, LivaNova, Inc., Advanced Bionics AG, MicroTransponder Inc., Axonics Modulation Technologies, Inc., Amplifon, MED-EL Medical Electronics., NeuroPace, Inc., NEVRO CORP., MEDICO S.p.A., Aleva Neurotherapeutics S.A., Second Sight, Cochlear Ltd., Sonova, Berlin Heart GmbH, SynCardia Systems LLC, and others.

Recent Developmental Activities in the Active Implantable Medical Devices Market:

• In November 2022, Cochlear Limited announced that the Cochlear Nucleus 8 Sound Processor received approval from the US Food and Drug Administration (FDA). The Nucleus 8 Sound Processor was described as the smallest and lightest behind-the-ear cochlear implant sound processor available in the industry.
• In August 2021, MicroTransponder secured approval from the US FDA for its Vivistim Paired VNS System, a drug-free, implantable stroke rehabilitation system to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke.
• In June 2021, Medtronic received the US FDA approval for its spinal cord stimulation implant Vanta, used for chronic pain. It is a non-rechargeable device promising nearly double the battery life of previous hardware.

Key Takeaways from the Active Implantable Medical Devices Market Report Study

• Market size analysis for current active implantable medical devices market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the active implantable medical devices market.
• Various opportunities available for the other competitors in the active implantable medical devices market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current active implantable medical devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for active implantable medical devices market growth in the coming future?

Target Audience who can be benefited from this Active Implantable Medical Devices Market Report Study

• Active implantable medical devices product providers
• Research organizations and consulting companies
• Active implantable medical devices-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in active implantable medical devices
• Various end-users who want to know more about the active implantable medical devices market and the latest technological developments in the active implantable medical devices market

Frequently Asked Questions for the Active Implantable Medical Devices Market:

1. What are Active Implantable Medical Devices?

Active implantable medical devices are intended to be totally or partially introduced into the human body for diagnostic or therapeutic purposes and are to remain in place. It includes a wide range of devices, including pacemakers, defibrillators, infusion pumps, ventricular assist systems and devices, cochlear implants, and neurostimulators.

2. What is the market for Active Implantable Medical Devices?

The active implantable medical devices market was valued at USD 25 billion in 2023, growing at a CAGR of 7.55% during the forecast period from 2024 to 2030 to reach USD 38.57 billion by 2030.

3. What are the drivers for the Active Implantable Medical Devices market?

The active implantable medical devices market is observing substantial market growth primarily owing to the increasing instances of chronic disorders like neurological disorders including multiple sclerosis, epilepsy, chronic lower back pain, increasing regulatory approvals, and the rising preference for minimally invasive procedures that are anticipated to further accelerate the overall growth of the active implantable medical devices market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the Active Implantable Medical Devices market?

Some of the key market players operating in active implantable medical devices include Medtronic, Abbott, Jarvik Heart, Inc., Biotronik SE & Co. KG, Boston Scientific Corporation, LivaNova, Inc., Advanced Bionics AG, MicroTransponder Inc., Axonics Modulation Technologies, Inc., Amplifon, MED-EL Medical Electronics., NeuroPace, Inc., NEVRO CORP., MEDICO S.p.A., Aleva Neurotherapeutics S.A., Second Sight, Cochlear Ltd., Sonova, Berlin Heart GmbH, SynCardia Systems LLC, and others.

5. Which region has the highest share in the Active Implantable Medical Devices market?

North America is expected to dominate the overall Active Implantable Medical Devices market during the forecast period from 2024 to 2030. This can be attributed to several factors, including the increasing prevalence of hearing loss, the growing burden of cardiovascular disorders in the region including myocardial infarction, and ongoing product developmental activities by regulatory bodies that are acting as key factors contributing to the growth of the active implantable medical devices market in the North America region.